BIOLIDICS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.012 SGD | 0.00% |
|
0.00% | -14.29% |
| Apr. 12 | Biolidics Limited Announces the Redesignation of Zhu Hua from Non-Executive Non-Independent Director to Executive Director | CI |
| Apr. 12 | Singapore Shares Fall at Market Close; Biolidics Up 9% | MT |
| Sales 2021 | 2.33M 1.71M | Sales 2022 | 2.54M 1.86M | Capitalization | 11.84M 8.67M |
|---|---|---|---|---|---|
| Net income 2021 | -5M -3.66M | Net income 2022 | -9M -6.59M | EV / Sales 2021 | 21.8 x |
| Net Debt 2021 | 289K 212K | Net cash position 2022 | 2.02M 1.48M | EV / Sales 2022 | 3.87 x |
| P/E ratio 2021 |
-8.41
x | P/E ratio 2022 |
-0.72
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 54.05% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -8.33% | ||
| 1 week | -8.33% | ||
| Current month | -8.33% | ||
| 1 month | -8.33% | ||
| 3 months | -15.38% | ||
| 6 months | -31.25% | ||
| Current year | -21.43% |
1 week
0.01
0.01
1 month
0.010.01
Current year
0.010.01
1 year
0.010.02
3 years
0.010.35
5 years
0.010.89
10 years
0.010.89
| Managers | Title | Age | Since |
|---|---|---|---|
Tang Yih Song
CEO | Chief Executive Officer | 59 | 21-08-31 |
Hafiza Alwi Nor
SEC | Corporate Secretary | - | - |
Yeung Sau Siu
AUD | Comptroller/Controller/Auditor | 50 | 22-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tang Yih Song
CEO | Chief Executive Officer | 59 | 21-08-31 |
Li-Ling Ch'ng
BRD | Director/Board Member | 53 | 23-03-30 |
Yoke Pheng Liew
BRD | Director/Board Member | 68 | Nov. 26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 0.012 | 0.00% | 2 985 500 |
| 24-04-12 | 0.012 | +9.09% | 5,106,300 |
| 24-04-11 | 0.011 | -8.33% | 206,900 |
| 24-04-09 | 0.012 | +9.09% | 2,025,000 |
Delayed Quote Singapore S.E., April 16, 2024 at 12:58 am EDT
More quotes
Biolidics Limited is a Singapore-based precision medicine medical technology company. The principal activities of the Company are technology development, technology transfer, marketing, selling and distribution of biomedical technology, life and medicine science related products and services; provision of laboratory services; and investment holding. It has three segments: cancer diagnostics, infectious diseases and laboratory services. Cancer diagnostics segment develops and commercializes the ClearCell FX1 System, a fully automated CE-IVD medical device which, separate and enrich cancer cells from blood, allows users of the system to perform liquid biopsies. Infectious diseases segment develops, markets and/or distributes certified test kits with various diagnostic partners. Laboratory services segment offers a range of tests. The laboratory has a regulatory approval from Singapore's Ministry of Health for molecular microbiology testing and PCR testing services for COVID-19 in Singapo
Calendar
2024-04-25
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.43% | 6.56M | |
| +5.10% | 213B | |
| +3.60% | 177B | |
| +11.86% | 134B | |
| +16.66% | 99.13B | |
| +0.34% | 63.47B | |
| +16.98% | 53.69B | |
| -4.51% | 46.36B | |
| +0.86% | 41.09B | |
| +11.39% | 39.3B |
- Stock Market
- Equities
- 8YY Stock
